Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Korsana Biosciences, Inc.CYCN · Entity 7698 | Director · 10% owner | July 16, 2026 | July 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Korsana Biosciences, Inc.
Report date July 16, 2026 · Filed July 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 910,240 |
Reported balance
After 2026-07-16 transaction · row 1
1 source rowRow 1 · 2026-07-16 · Conversion · Acquired 351,037 · Balance 910,240 F1: On May 19, 2023, the reporting person purchased directly from the Issuer 351,037 shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") at a price of $8.68 per share in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 31, 2023 between the reporting person and the Issuer. The Series A Preferred Stock is convertible to Common Stock on a one-for-one basis at the option of the holder thereof. On July 16, 2026, the reporting person converted all 351,037 shares of Series A Convertible Preferred Stock into 351,037 shares of Common Stock. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-07-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-16 · Conversion · Disposed 351,037 · Balance 0 F1: On May 19, 2023, the reporting person purchased directly from the Issuer 351,037 shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") at a price of $8.68 per share in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 31, 2023 between the reporting person and the Issuer. The Series A Preferred Stock is convertible to Common Stock on a one-for-one basis at the option of the holder thereof. On July 16, 2026, the reporting person converted all 351,037 shares of Series A Convertible Preferred Stock into 351,037 shares of Common Stock. F3: All options to purchase Common Stock previously held by the reporting person were cancelled on July 16, 2026. As a result, the reporting person no longer holds options to purchase Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectThe 2000 Trust for Alexis Mae Hecht | 24 |
Reported balance
Holding disclosure · report date 2026-07-16 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 24 F2: These shares are held in the referenced trust for the benefit of the reporting person's child. The reporting person's spouse is the trustee of this trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectThe 2000 Trust for Malcolm Paul Hecht | 24 |
Reported balance
Holding disclosure · report date 2026-07-16 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 24 F2: These shares are held in the referenced trust for the benefit of the reporting person's child. The reporting person's spouse is the trustee of this trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectThe 2000 Trust for Zoe Niovi Hecht | 24 |
Reported balance
Holding disclosure · report date 2026-07-16 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 24 F2: These shares are held in the referenced trust for the benefit of the reporting person's child. The reporting person's spouse is the trustee of this trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 19, 2023, the reporting person purchased directly from the Issuer 351,037 shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") at a price of $8.68 per share in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 31, 2023 between the reporting person and the Issuer. The Series A Preferred Stock is convertible to Common Stock on a one-for-one basis at the option of the holder thereof. On July 16, 2026, the reporting person converted all 351,037 shares of Series A Convertible Preferred Stock into 351,037 shares of Common Stock.
F2: These shares are held in the referenced trust for the benefit of the reporting person's child. The reporting person's spouse is the trustee of this trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or any other purpose.
F3: All options to purchase Common Stock previously held by the reporting person were cancelled on July 16, 2026. As a result, the reporting person no longer holds options to purchase Common Stock.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
IRONWOOD PHARMACEUTICALS INC
Report date April 01, 2019 · Filed April 03, 2019
Section 16 reporting ended · disclosed 2019-04-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.88 · Expires 2019-07-28 | Direct | 20,000 |
Reported balance
After 2019-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-04-01 · Disposition to issuer · Disposed 20,000 · Balance 20,000 F1: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"). In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F2: The remaining 20,000 shares are presently exercisable in full. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.89 · Expires 2021-02-01 | Direct | 130,980 |
Reported balance
After 2019-04-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-04-01 · Disposition to issuer · Disposed 44,020 · Balance 130,980 F3: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 44,020 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 130,980 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award. F4: This option, granted as an annual performance award, is presently exercisable in full. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.11 · Expires 2022-02-01 | Direct | 292,467 |
Reported balance
After 2019-04-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-04-01 · Disposition to issuer · Disposed 7,533 · Balance 292,467 F5: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 7,533 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 292,467 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award. F4: This option, granted as an annual performance award, is presently exercisable in full. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.65 · Expires 2023-02-01 | Direct | 367,355 |
Reported balance
After 2019-04-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-04-01 · Disposition to issuer · Disposed 7,645 · Balance 367,355 F6: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 7,645 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 367,355 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award. F4: This option, granted as an annual performance award, is presently exercisable in full. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.56 · Expires 2024-03-03 | Direct | 318,229 |
Reported balance
After 2019-04-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-04-01 · Disposition to issuer · Disposed 6,771 · Balance 318,229 F7: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 6,771 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 318,229 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award. F4: This option, granted as an annual performance award, is presently exercisable in full. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.12 · Expires 2026-03-01 | Direct | 723,125 |
Reported balance
After 2019-04-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-04-01 · Disposition to issuer · Disposed 166,875 · Balance 723,125 F1: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"). In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F8: The remaining 723,125 shares are presently exercisable in full. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.93 · Expires 2027-02-27 | Direct | 427,500 |
Reported balance
After 2019-04-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-04-01 · Disposition to issuer · Disposed 332,500 · Balance 427,500 F1: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"). In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F9: The remaining 427,500 shares are presently exercisable in full. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.95 · Expires 2028-02-21 | Direct | 181,250 |
Reported balance
After 2019-04-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-04-01 · Disposition to issuer · Disposed 398,750 · Balance 181,250 F1: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"). In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F10: The remaining 181,250 shares are presently exercisable in full. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.49 · Expires 2029-01-29 | Direct | 62,500 |
Reported balance
After 2019-04-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-04-01 · Disposition to issuer · Disposed 937,500 · Balance 62,500 F1: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"). In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F11: The remaining 62,500 shares are presently exercisable in full. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.02 · Expires 2020-02-02 | Direct | 125,000 |
Reported balance
Holding disclosure · report date 2019-04-01 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 125,000 F12: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the exercise price of the option was adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F4: This option, granted as an annual performance award, is presently exercisable in full. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.91 · Expires 2025-03-16 | Direct | 565,000 |
Reported balance
Holding disclosure · report date 2019-04-01 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 565,000 F12: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the exercise price of the option was adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F4: This option, granted as an annual performance award, is presently exercisable in full. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"). In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award.
F2: The remaining 20,000 shares are presently exercisable in full.
F3: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 44,020 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 130,980 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award.
F4: This option, granted as an annual performance award, is presently exercisable in full.
F5: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 7,533 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 292,467 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award.
F6: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 7,645 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 367,355 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award.
F7: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 6,771 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 318,229 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award.
F8: The remaining 723,125 shares are presently exercisable in full.
F9: The remaining 427,500 shares are presently exercisable in full.
F10: The remaining 181,250 shares are presently exercisable in full.
F11: The remaining 62,500 shares are presently exercisable in full.
F12: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the exercise price of the option was adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 16, 2026 Filed Jul 20, 2026 21:04 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | ConversionSeries A Convertible Preferred Stock · Derivative | 351,037 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-309048 · ownership.xml · derivative · entry 5 Hecht Peter M · CIK 0001478485 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 351,037 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 19, 2023, the reporting person purchased directly from the Issuer 351,037 shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") at a price of $8.68 per share in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 31, 2023 between the reporting person and the Issuer. The Series A Preferred Stock is convertible to Common Stock on a one-for-one basis at the option of the holder thereof. On July 16, 2026, the reporting person converted all 351,037 shares of Series A Convertible Preferred Stock into 351,037 shares of Common Stock. F1 · price: On May 19, 2023, the reporting person purchased directly from the Issuer 351,037 shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") at a price of $8.68 per share in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 31, 2023 between the reporting person and the Issuer. The Series A Preferred Stock is convertible to Common Stock on a one-for-one basis at the option of the holder thereof. On July 16, 2026, the reporting person converted all 351,037 shares of Series A Convertible Preferred Stock into 351,037 shares of Common Stock. F1 · derivative.exercise_date: On May 19, 2023, the reporting person purchased directly from the Issuer 351,037 shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") at a price of $8.68 per share in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 31, 2023 between the reporting person and the Issuer. The Series A Preferred Stock is convertible to Common Stock on a one-for-one basis at the option of the holder thereof. On July 16, 2026, the reporting person converted all 351,037 shares of Series A Convertible Preferred Stock into 351,037 shares of Common Stock. F1 · derivative.expiration_date: On May 19, 2023, the reporting person purchased directly from the Issuer 351,037 shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") at a price of $8.68 per share in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 31, 2023 between the reporting person and the Issuer. The Series A Preferred Stock is convertible to Common Stock on a one-for-one basis at the option of the holder thereof. On July 16, 2026, the reporting person converted all 351,037 shares of Series A Convertible Preferred Stock into 351,037 shares of Common Stock. F1 · derivative.underlying_shares: On May 19, 2023, the reporting person purchased directly from the Issuer 351,037 shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") at a price of $8.68 per share in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 31, 2023 between the reporting person and the Issuer. The Series A Preferred Stock is convertible to Common Stock on a one-for-one basis at the option of the holder thereof. On July 16, 2026, the reporting person converted all 351,037 shares of Series A Convertible Preferred Stock into 351,037 shares of Common Stock. F3 · balance_after: All options to purchase Common Stock previously held by the reporting person were cancelled on July 16, 2026. As a result, the reporting person no longer holds options to purchase Common Stock. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 21:04 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | ConversionCommon Stock | 351,037 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-309048 · ownership.xml · nonDerivative · entry 1 Hecht Peter M · CIK 0001478485 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 910,240 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 19, 2023, the reporting person purchased directly from the Issuer 351,037 shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") at a price of $8.68 per share in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 31, 2023 between the reporting person and the Issuer. The Series A Preferred Stock is convertible to Common Stock on a one-for-one basis at the option of the holder thereof. On July 16, 2026, the reporting person converted all 351,037 shares of Series A Convertible Preferred Stock into 351,037 shares of Common Stock. F1 · price: On May 19, 2023, the reporting person purchased directly from the Issuer 351,037 shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") at a price of $8.68 per share in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 31, 2023 between the reporting person and the Issuer. The Series A Preferred Stock is convertible to Common Stock on a one-for-one basis at the option of the holder thereof. On July 16, 2026, the reporting person converted all 351,037 shares of Series A Convertible Preferred Stock into 351,037 shares of Common Stock. Read SEC document |
| March 25, 2025 Filed Mar 28, 2025 00:38 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantCommon Stock | 181,818 | $2.75 | $499,999.50 |
DisclosureSEC source: 0000950170-25-046280 · ownership.xml · nonDerivative · entry 1 Hecht Peter M · CIK 0001478485 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 559,203 F1 · shares: On March 25, 2025, the reporting person purchased directly from the Issuer 181,818 shares of Common Stock for a total purchase price of approximately $500,000 (or $2.75 per share) in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 21, 2025 by and among the Issuer and the investors named therein. Read SEC document |
| January 01, 2024 Filed Jan 26, 2024 21:07 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-007920 · ownership.xml · nonDerivative · entry 1 Hecht Peter M · CIK 0001478485 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 377,385 F1 · shares: The Reporting Person was granted 15,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. These 15,000 shares are subject to vesting over a 47- month period, provided that the Reporting Person remains a consultant to the Cyclerion Therapeutics or a member of the board of directors of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 21:05 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-067738 · ownership.xml · nonDerivative · entry 2 Hecht Peter M · CIK 0001478485 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 362,385 F2 · shares: The Reporting Person was granted 15,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. These 15,000 shares are subject to vesting over a 48- month period, provided that the Reporting Person remains a consultant to the Cyclerion Therapeutics or a member of the board of directors of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. Read SEC document |
| November 30, 2023 Filed Dec 4, 2023 21:05 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-067738 · ownership.xml · nonDerivative · entry 1 Hecht Peter M · CIK 0001478485 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 347,385 F1 · shares: The Reporting Person was granted 20,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. 2,500 of the shares vest immediately and the remaining 17,500 shares are subject to vesting ratably over a 42-month period, provided that the Reporting Person remains as a director of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. Read SEC document |
| May 19, 2023 Filed May 23, 2023 00:43 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantSeries A Convertible Preferred Stock · Derivative | 351,037 | $8.68 Strike: $0.00 | $3,047,001.16 |
DisclosureSEC source: 0001140361-23-026101 · form4.xml · derivative · entry 5 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 351,037 Underlying: Common Stock · 351,037 shares Expires not disclosed F1 · shares: On May 19, 2023, the reporting person purchased directly from the Issuer 225,000 shares of Common Stock and 351,037 shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") for a total purchase price of approximately $5,000,000 (or $8.68 per share) in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 31, 2023 between the reporting person and the Issuer. The Series A Preferred Stock may be converted to Common Stock on a one-for-one basis at the option of the holder thereof. The reporting person has agreed not to convert his Series A Preferred Stock to the extent such conversion would require shareholder approval pursuant to Nasdaq listing rules and such shareholder approval has not been obtained. F1 · derivative.exercise_date: On May 19, 2023, the reporting person purchased directly from the Issuer 225,000 shares of Common Stock and 351,037 shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") for a total purchase price of approximately $5,000,000 (or $8.68 per share) in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 31, 2023 between the reporting person and the Issuer. The Series A Preferred Stock may be converted to Common Stock on a one-for-one basis at the option of the holder thereof. The reporting person has agreed not to convert his Series A Preferred Stock to the extent such conversion would require shareholder approval pursuant to Nasdaq listing rules and such shareholder approval has not been obtained. F1 · derivative.expiration_date: On May 19, 2023, the reporting person purchased directly from the Issuer 225,000 shares of Common Stock and 351,037 shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") for a total purchase price of approximately $5,000,000 (or $8.68 per share) in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 31, 2023 between the reporting person and the Issuer. The Series A Preferred Stock may be converted to Common Stock on a one-for-one basis at the option of the holder thereof. The reporting person has agreed not to convert his Series A Preferred Stock to the extent such conversion would require shareholder approval pursuant to Nasdaq listing rules and such shareholder approval has not been obtained. Read SEC document |
| May 19, 2023 Filed May 23, 2023 00:43 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantCommon Stock | 225,000 | $8.68 | $1,953,000.00 |
DisclosureSEC source: 0001140361-23-026101 · form4.xml · nonDerivative · entry 1 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 327,385 F1 · shares: On May 19, 2023, the reporting person purchased directly from the Issuer 225,000 shares of Common Stock and 351,037 shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") for a total purchase price of approximately $5,000,000 (or $8.68 per share) in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 31, 2023 between the reporting person and the Issuer. The Series A Preferred Stock may be converted to Common Stock on a one-for-one basis at the option of the holder thereof. The reporting person has agreed not to convert his Series A Preferred Stock to the extent such conversion would require shareholder approval pursuant to Nasdaq listing rules and such shareholder approval has not been obtained. Read SEC document |
| January 20, 2022 Filed Jan 24, 2022 16:38 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 430,000 | $0.00 Strike: $1.21 | $0.00 |
DisclosureSEC source: 0001140361-22-002453 · form4.xml · derivative · entry 2 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,000 Underlying: Common Stock · 430,000 shares Expires 2032-01-20 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 20, 2022. Read SEC document |
| January 03, 2022 Filed Jan 24, 2022 16:38 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 52,950 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0001140361-22-002453 · form4.xml · derivative · entry 1 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,950 Underlying: Common Stock · 52,950 shares Expires 2032-01-03 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 8.33333% of the shares of Common Stock on each monthly anniversary of January 3, 2022. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 21:25 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | PurchaseCommon Stock | 823,170 | $3.28 | $2,699,997.60 |
DisclosureSEC source: 0001140361-21-020090 · form4.xml · nonDerivative · entry 1 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,047,698 F1 · shares: On June 3, 2021, the reporting person agreed to purchase directly from the Issuer 823,170 shares of Common Stock of the Issuer in a private placement transaction. Read SEC document |
| May 06, 2021 Filed May 10, 2021 12:45 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | PurchaseCommon Stock | 302,000 | $2.43 | $733,860.00 |
DisclosureSEC source: 0001140361-21-016532 · form4.xml · nonDerivative · entry 1 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,224,528 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.31 to $2.59, inclusive. The reporting person will provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| May 05, 2021 Filed May 7, 2021 01:27 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | PurchaseCommon Stock | 398,001 | $2.53 | $1,006,942.53 |
DisclosureSEC source: 0001140361-21-016304 · form4.xml · nonDerivative · entry 2 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 922,528 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.32 to $2.61, inclusive. The reporting person will provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| May 04, 2021 Filed May 7, 2021 01:27 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | PurchaseCommon Stock | 300,000 | $2.29 | $687,000.00 |
DisclosureSEC source: 0001140361-21-016304 · form4.xml · nonDerivative · entry 1 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 524,527 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.10 to $2.45, inclusive. The reporting person will provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 20:59 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 153,846 | $2.65 Strike: $2.65 | $407,691.90 |
DisclosureSEC source: 0001209191-20-022657 · doc4.xml · derivative · entry 5 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,846 Underlying: Common Stock · 153,846 shares Expires 2030-03-31 F3 · shares: The Compensation Committee approved the stock option award to the reporting person in order to offset his low-to-market total cash compensation and provide him with a market-aligned total compensation package for 2019, 2020, and 2021. 36,436 options under the award are intended to offset his below-market total cash salary for 2019, and 58,705 options under the award are intended to offset his below-market total cash compensation for each of 2020 and 2021. F4 · derivative.exercise_date: The options, granted as an annual performance award, vests in seventy-two equal monthly installments over a six year period on each monthly anniversary of January 1, 2020 until fully vested. Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 22:43 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001209191-19-058165 · doc4.xml · derivative · entry 1 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-11-22 F1 · derivative.exercise_date: The stock option grant will vest and become exercisable upon the attainment of both performance-based and service-based hurdles, as follows: (i) 20% of the shares subject to the option, if the average closing price of the common stock reported by Nasdaq for any thirty (30) consecutive trading days equals or exceeds $10; plus an additional (ii) 40% of the shares, if the average closing price equals or exceeds $20; plus an additional (iii) 40% of the shares, if the average closing price equals or exceeds $30; in each case, subject to the continuous employment or service through the later of the date that the performance hurdles set forth above are attained (but no later than December 31, 2024) and December 31, 2021. F2 · derivative.expiration_date: To the extent unvested as of December 31, 2024, all unvested shares underlying such performance-based option will be cancelled. Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 20:09 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $6.04 | $0.00 |
DisclosureSEC source: 0001209191-19-041920 · doc4.xml · derivative · entry 5 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2019-07-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option to purchase 20,167 shares vests in installments upon achievement of certain regulatory and commercial milestones. The option has vested as to 2,000 shares as of the date hereof. Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 20:09 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | Exercise / conversionCommon Stock | 2,000 | $6.04 | $12,080.00 |
DisclosureSEC source: 0001209191-19-041920 · doc4.xml · nonDerivative · entry 1 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,192 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction represents the acquisition of common stock as a result of the exercise and hold of derivative securities reported in Table II. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:08 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 937,500 | Not disclosed Strike: $11.49 | Not disclosed |
DisclosureSEC source: 0001209191-19-023427 · doc4.xml · derivative · entry 9 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Class A Common Stock · 937,500 shares Expires 2029-01-29 F1 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"). In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F1 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"). In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F1 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"). In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F11 · derivative.exercise_date: The remaining 62,500 shares are presently exercisable in full. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:08 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 398,750 | Not disclosed Strike: $12.95 | Not disclosed |
DisclosureSEC source: 0001209191-19-023427 · doc4.xml · derivative · entry 8 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,250 Underlying: Class A Common Stock · 398,750 shares Expires 2028-02-21 F1 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"). In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F1 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"). In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F1 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"). In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F10 · derivative.exercise_date: The remaining 181,250 shares are presently exercisable in full. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:08 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 332,500 | Not disclosed Strike: $14.93 | Not disclosed |
DisclosureSEC source: 0001209191-19-023427 · doc4.xml · derivative · entry 7 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427,500 Underlying: Class A Common Stock · 332,500 shares Expires 2027-02-27 F1 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"). In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F1 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"). In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F1 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"). In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F9 · derivative.exercise_date: The remaining 427,500 shares are presently exercisable in full. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:08 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 166,875 | Not disclosed Strike: $9.12 | Not disclosed |
DisclosureSEC source: 0001209191-19-023427 · doc4.xml · derivative · entry 6 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 723,125 Underlying: Class A Common Stock · 166,875 shares Expires 2026-03-01 F1 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"). In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F1 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"). In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F1 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"). In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F8 · derivative.exercise_date: The remaining 723,125 shares are presently exercisable in full. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:08 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 6,771 | Not disclosed Strike: $12.56 | Not disclosed |
DisclosureSEC source: 0001209191-19-023427 · doc4.xml · derivative · entry 5 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,229 Underlying: Class A Common Stock · 6,771 shares Expires 2024-03-03 F7 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 6,771 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 318,229 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award. F7 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 6,771 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 318,229 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award. F7 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 6,771 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 318,229 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award. F4 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:08 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 7,645 | Not disclosed Strike: $11.65 | Not disclosed |
DisclosureSEC source: 0001209191-19-023427 · doc4.xml · derivative · entry 4 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,355 Underlying: Class A Common Stock · 7,645 shares Expires 2023-02-01 F6 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 7,645 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 367,355 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award. F6 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 7,645 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 367,355 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award. F6 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 7,645 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 367,355 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award. F4 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:08 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 7,533 | Not disclosed Strike: $13.11 | Not disclosed |
DisclosureSEC source: 0001209191-19-023427 · doc4.xml · derivative · entry 3 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,467 Underlying: Class A Common Stock · 7,533 shares Expires 2022-02-01 F5 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 7,533 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 292,467 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award. F5 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 7,533 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 292,467 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award. F5 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 7,533 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 292,467 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award. F4 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:08 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 44,020 | Not disclosed Strike: $9.89 | Not disclosed |
DisclosureSEC source: 0001209191-19-023427 · doc4.xml · derivative · entry 2 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,980 Underlying: Class A Common Stock · 44,020 shares Expires 2021-02-01 F3 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 44,020 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 130,980 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award. F3 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 44,020 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 130,980 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award. F3 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 44,020 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 130,980 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award. F4 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:08 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $4.88 | Not disclosed |
DisclosureSEC source: 0001209191-19-023427 · doc4.xml · derivative · entry 1 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Class A Common Stock · 20,000 shares Expires 2019-07-28 F1 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"). In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F1 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"). In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F1 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"). In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F2 · derivative.exercise_date: The remaining 20,000 shares are presently exercisable in full. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:30 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 857,977 | $0.00 Strike: $14.20 | $0.00 |
DisclosureSEC source: 0001209191-19-023556 · doc4.xml · derivative · entry 15 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 857,977 Underlying: Common Stock · 857,977 shares Expires 2029-01-29 F3 · derivative.exercise_price: Represents options to purchase shares of Cyclerion common stock granted to the reporting person in connection with the Separation. F9 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of common stock on each monthly anniversary of January 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:30 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 380,393 | $0.00 Strike: $16.02 | $0.00 |
DisclosureSEC source: 0001209191-19-023556 · doc4.xml · derivative · entry 14 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,393 Underlying: Common Stock · 380,393 shares Expires 2028-02-21 F3 · derivative.exercise_price: Represents options to purchase shares of Cyclerion common stock granted to the reporting person in connection with the Separation. F8 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of common stock on each monthly anniversary of January 1, 2018. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:30 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 344,829 | $0.00 Strike: $18.46 | $0.00 |
DisclosureSEC source: 0001209191-19-023556 · doc4.xml · derivative · entry 13 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,829 Underlying: Common Stock · 344,829 shares Expires 2027-02-27 F3 · derivative.exercise_price: Represents options to purchase shares of Cyclerion common stock granted to the reporting person in connection with the Separation. F7 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of common stock on each monthly anniversary of January 1, 2017. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:30 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 223,919 | $0.00 Strike: $11.28 | $0.00 |
DisclosureSEC source: 0001209191-19-023556 · doc4.xml · derivative · entry 12 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,919 Underlying: Common Stock · 223,919 shares Expires 2026-03-01 F3 · derivative.exercise_price: Represents options to purchase shares of Cyclerion common stock granted to the reporting person in connection with the Separation. F6 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of common stock on each monthly anniversary of January 1, 2016. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:30 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 56,500 | $0.00 Strike: $17.20 | $0.00 |
DisclosureSEC source: 0001209191-19-023556 · doc4.xml · derivative · entry 11 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,500 Underlying: Common Stock · 56,500 shares Expires 2025-03-16 F3 · derivative.exercise_price: Represents options to purchase shares of Cyclerion common stock granted to the reporting person in connection with the Separation. F5 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:30 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 37,973 | $0.00 Strike: $15.54 | $0.00 |
DisclosureSEC source: 0001209191-19-023556 · doc4.xml · derivative · entry 10 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,973 Underlying: Common Stock · 37,973 shares Expires 2024-03-03 F3 · derivative.exercise_price: Represents options to purchase shares of Cyclerion common stock granted to the reporting person in connection with the Separation. F5 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:30 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 43,680 | $0.00 Strike: $14.40 | $0.00 |
DisclosureSEC source: 0001209191-19-023556 · doc4.xml · derivative · entry 9 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,680 Underlying: Common Stock · 43,680 shares Expires 2023-02-01 F3 · derivative.exercise_price: Represents options to purchase shares of Cyclerion common stock granted to the reporting person in connection with the Separation. F5 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:30 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 36,089 | $0.00 Strike: $16.21 | $0.00 |
DisclosureSEC source: 0001209191-19-023556 · doc4.xml · derivative · entry 8 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,089 Underlying: Common Stock · 36,089 shares Expires 2022-02-01 F3 · derivative.exercise_price: Represents options to purchase shares of Cyclerion common stock granted to the reporting person in connection with the Separation. F5 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:30 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 53,090 | $0.00 Strike: $12.23 | $0.00 |
DisclosureSEC source: 0001209191-19-023556 · doc4.xml · derivative · entry 7 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,090 Underlying: Common Stock · 53,090 shares Expires 2021-02-01 F3 · derivative.exercise_price: Represents options to purchase shares of Cyclerion common stock granted to the reporting person in connection with the Separation. F5 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:30 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 12,499 | $0.00 Strike: $12.39 | $0.00 |
DisclosureSEC source: 0001209191-19-023556 · doc4.xml · derivative · entry 6 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,499 Underlying: Common Stock · 12,499 shares Expires 2020-02-02 F3 · derivative.exercise_price: Represents options to purchase shares of Cyclerion common stock granted to the reporting person in connection with the Separation. F5 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:30 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $6.04 | $0.00 |
DisclosureSEC source: 0001209191-19-023556 · doc4.xml · derivative · entry 5 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2019-07-28 F3 · derivative.exercise_price: Represents options to purchase shares of Cyclerion common stock granted to the reporting person in connection with the Separation. F4 · derivative.exercise_date: This option to purchase 20,170 shares vests in installments upon achievement of certain regulatory and commercial milestones. The option has vested as to 2,000 shares as of the date hereof. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:30 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantCommon Stock | 485 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-023556 · doc4.xml · nonDerivative · entry 4 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · The 2000 Trust for Zoe Niovi Hecht Disclosed balance after: 485 F2 · shares: These shares are held in the referenced trust for the benefit of the reporting person's child. The reporting person's spouse is the trustee of this trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or any other purpose. F2 · ownership.nature: These shares are held in the referenced trust for the benefit of the reporting person's child. The reporting person's spouse is the trustee of this trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or any other purpose. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:30 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantCommon Stock | 485 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-023556 · doc4.xml · nonDerivative · entry 3 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · The 2000 Trust for Malcolm Paul Hecht Disclosed balance after: 485 F2 · shares: These shares are held in the referenced trust for the benefit of the reporting person's child. The reporting person's spouse is the trustee of this trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or any other purpose. F2 · ownership.nature: These shares are held in the referenced trust for the benefit of the reporting person's child. The reporting person's spouse is the trustee of this trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or any other purpose. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:30 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantCommon Stock | 485 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-023556 · doc4.xml · nonDerivative · entry 2 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · The 2000 Trust for Alexis Mae Hecht Disclosed balance after: 485 F2 · shares: These shares are held in the referenced trust for the benefit of the reporting person's child. The reporting person's spouse is the trustee of this trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or any other purpose. F2 · ownership.nature: These shares are held in the referenced trust for the benefit of the reporting person's child. The reporting person's spouse is the trustee of this trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or any other purpose. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:30 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantCommon Stock | 223,192 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-023556 · doc4.xml · nonDerivative · entry 1 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,192 F1 · shares: In Connection with the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"), the reporting person received Cyclerion shares representing an equitable adjustment of Ironwood shares held by the reporting person prior to the separation. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 20:05 UTC Amendment | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 857,830 | $0.00 Strike: $14.21 | $0.00 |
DisclosureSEC source: 0001209191-19-050311 · doc4a.xml · derivative · entry 9 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 857,830 Underlying: Common Stock · 857,830 shares Expires 2029-01-29 F2 · derivative.exercise_price: This report has been amended to correct the exercise price of the stock options that were originally issued by Ironwood in connection with the Separation. F8 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 1, 2019. F4 · balance_after: This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 20:05 UTC Amendment | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 380,330 | $0.00 Strike: $16.02 | $0.00 |
DisclosureSEC source: 0001209191-19-050311 · doc4a.xml · derivative · entry 8 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,330 Underlying: Common Stock · 380,330 shares Expires 2028-02-21 F7 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 1, 2018. F4 · balance_after: This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 20:05 UTC Amendment | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 344,777 | $0.00 Strike: $18.47 | $0.00 |
DisclosureSEC source: 0001209191-19-050311 · doc4a.xml · derivative · entry 7 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,777 Underlying: Common Stock · 344,777 shares Expires 2027-02-27 F2 · derivative.exercise_price: This report has been amended to correct the exercise price of the stock options that were originally issued by Ironwood in connection with the Separation. F6 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 1, 2017. F4 · balance_after: This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 20:05 UTC Amendment | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 223,893 | $0.00 Strike: $11.28 | $0.00 |
DisclosureSEC source: 0001209191-19-050311 · doc4a.xml · derivative · entry 6 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,893 Underlying: Common Stock · 223,893 shares Expires 2026-03-01 F5 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 1, 2016. F4 · balance_after: This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 20:05 UTC Amendment | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 37,972 | $0.00 Strike: $15.54 | $0.00 |
DisclosureSEC source: 0001209191-19-050311 · doc4a.xml · derivative · entry 5 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,972 Underlying: Common Stock · 37,972 shares Expires 2024-03-03 F3 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. F4 · balance_after: This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 20:05 UTC Amendment | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 43,679 | $0.00 Strike: $14.40 | $0.00 |
DisclosureSEC source: 0001209191-19-050311 · doc4a.xml · derivative · entry 4 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,679 Underlying: Common Stock · 43,679 shares Expires 2023-02-01 F3 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. F4 · balance_after: This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 20:05 UTC Amendment | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 36,088 | $0.00 Strike: $16.21 | $0.00 |
DisclosureSEC source: 0001209191-19-050311 · doc4a.xml · derivative · entry 3 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,088 Underlying: Common Stock · 36,088 shares Expires 2022-02-01 F3 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. F4 · balance_after: This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 20:05 UTC Amendment | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 53,083 | $0.00 Strike: $12.24 | $0.00 |
DisclosureSEC source: 0001209191-19-050311 · doc4a.xml · derivative · entry 2 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,083 Underlying: Common Stock · 53,083 shares Expires 2021-02-01 F2 · derivative.exercise_price: This report has been amended to correct the exercise price of the stock options that were originally issued by Ironwood in connection with the Separation. F3 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. F4 · balance_after: This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.